The aberrant activation of developmental processes triggers diverse cancer types. Chordoma is a rare, aggressive tumor arising from transformed notochord remnants. Several potentially oncogenic factors, including several receptor tyrosine kinase (RTK) genes, have been found deregulated in chordoma, yet causation remains uncertain. In particular, sustained expression of the developmental notochord transcription factor Brachyury is hypothesized as key driver of chordoma; nonetheless, experimental evidence for an oncogenic role of Brachyury in chordoma and its prognostic impact remains missing. Here, we developed and applied a zebrafish chordoma model to identify the notochord-transforming potential of implicated genes in vivo. We find that Brachyury, including a form with augmented transcriptional activity, is insufficient to initiate notochord hyperplasia. In contrast, the chordoma-implicated RTKs EGFR and KDR/VEGFR2 are sufficient to transform notochord cells within two to five days of development. Transcriptome and structural analysis of transformed notochords revealed that the aberrant activation of RTK/Ras signaling attenuates processes required for notochord differentiation, including of the unfolded protein response. Our results provide first in vivo indication against a tumor-initiating potential of Brachyury in the notochord, and imply activated RTK signaling as possibly initiating event in chordoma. These results provide a mechanistic framework for the pursuit of chemotherapeutic compounds to combat this aggressive tumor type.
Introduction
Different genetic lesions can result in the malignant transformation of individual cells, ultimately leading to cancer. In particular, the reactivation or overexpression of developmental transcription factor genes has been repeatedly uncovered in a variety of tumors. Constitutive activation of developmental signaling pathways is even more common, in particular by activating mutations and amplifications of receptor tyrosine kinase (RTK) genes including EGFR, FGFR, or VEGFR. The permissive and instructive functions of these factors deployed in the embryo, reactivated or maintained unchecked in adult tissues, endow transformed cells with malignant properties of hyperproliferation, stemness, and tissue invasion. Nonetheless, the relationship between developmental regulators and maintenance of lineage identity for a given cancer's cell of origin remains challenging to decipher.
Chordoma is a rare, slow-growing tumor typically occurring at the base of the skull or in sacrococcygeal regions along the spine (OMIM #215400). Chordomas are thought to result from malignant transformations of remnant cells of the embryonic notochord, a cartilaginous structure of mesodermal origin that supports embryo axis formation and spinal column formation before regressing during development (1). Despite its proposed origin from embryonic notochord cells, chordoma is typically first diagnosed in adults between ages 40 to 70, with an annual incidence of one case per million per year. Surgical removal of the tumor remains the most effective therapeutic option. Nonetheless, due to the deep tissue localization of chordomas, surgery of the strongly radio-and chemoresistant tumor is highly delicate or, in individual cases, even impossible. In addition, first treatment frequently results in re-occurring local tumors and possible metastases even after seemingly successful removal of the initial lesion. No proven systemic therapies are available for patients with reoccurring or non-resectable disease, nor against the ultimately fatal distant metastases (2) .
To date, no single molecular pathway can be assigned as a fundamental chordoma-driving mechanism.
Genomic sequencing of patient chordoma samples continues to uncover mutated genomic loci including PTEN (3), the Tuberous Sclerosis Complex (TSC) genes (4), TP53 (5) , and BCL6 (6) . Further, chordoma samples repeatedly feature increased expression, amplifications, or possibly activating mutations in several receptor tyrosine kinase (RTK) genes, including EGFR and the chromosome 4q12 genes KDR/VEGFR2, KIT, and PDGFRA2 that relay their activity through Ras (7) (8) (9) (10) . Emphasizing the potential significance of reoccurring RTK involvement, EGF pathway inhibitors have been shown to curb the growth of chordoma cell lines and xenografts (11) . Clinical trials have been performed using a variety of RTK inhibitors, including imatinib, sunitinib, and EGFR inhibitors, as well as the mTOR inhibitor rapamycin combined with imatinib (2) .
A seemingly consistent feature of chordoma is the expression of the T-box transcription factor T/Brachyury (12) . During development, Brachyury influences the formation of individual mesodermal fates, and is in particular an evolutionarily conserved regulator of the notochord (13) . Intriguingly, the genomic locus encoding for Brachyury has been found to be duplicated or further amplified in familial and sporadic chordoma cases (12, 14) . This data, together with detectable Brachyury expression in the vast majority of chordomas, points to a tumor origin from transformed remnant notochord cells. The transient nature of the notochord, which disappears before birth, and persistence of notochord cells in chordoma suggest that malignant transformation could depend on an early developmental pathway that maintains a notochord or early mesodermal program in remnant notochord cells. Brachyury expression is also increasingly reported from other cancers of the lung, small intestine, stomach, kidney, bladder, uterus, ovary, and testis, and its expression correlates with epithelial-to-mesenchymal transition (EMT), maintenance of an undifferentiated state, resistance of lung cancer cells to EGFR inhibition (15) . Brachyury is suggested to inhibit the cell cycle by downregulating CCND1 (CyclinD), RB (pRb), and CDKN1A (p21), ultimately decreasing the susceptibility of tumor cells to cytotoxic therapies (16) . Nonetheless, recent notochord-specific knockdown of Brachyury in mouse revealed that its activity is dispensable for notochord proliferation and EMT, questioning the potency of Brachyury mis-or overexpression alone to mediate chordoma formation (17) . Consequently, the influence of Brachyury expression on chordoma initiation and tumor maintenance in vivo remains speculative, as are the pathways that maintain the notochord in an oncogenic progenitor state.
The lack of a unifying mechanism leading to chordoma formation necessitates animal models that recapitulate key aspects of the disease. Given the developmental origins of chordoma, the zebrafish offers a unique opportunity to dissect the mechanisms of tumor initiation and progression. Controlled by regulators including Brachyury that drive deeply conserved notochord-forming mechanisms across vertebrates, the early notochord is principally formed by central vacuolated cells that provide hydraulic stability. In zebrafish, Notchsignaling dependent differentiation results in an epithelial layer of outer sheath cells (18) . The sheath cells surround the vacuole cells and secrete an extracellular matrix (ECM) composed of collagens, laminins, and proteoglycans that encapsulate the notochord. Work in medaka has established that endoplasmic reticulum (ER) stress occurs physiologically during this process, which requires the unfolded protein response (UPR) transducers Atf6 and Creb3l2 for the proper alignment of the notochord cells and for export of type II collagen (19, 20) . Notochord formation in Xenopus has also been linked to the progressive activation of UPR via Xbp1 and Creb3l2 to drive its differentiation (21) . Subsequently, the notochord ossifies to form the spine segments, while remnant notochord cells turn into the gel-like nucleus pulposus inside the intervertebral disks of the spinal column (22, 23) .
We recently established in zebrafish the first animal proxy for chordoma onset based on notochord-specific expression of HRAS V12 that recapitulates oncogenic RTK/Ras pathway activation (24) . Our model uses the bimodal Gal4/UAS system, in which a notochord-specific transgene expresses the Gal4 transcription factor that drives a separate candidate transgene with Upstream Activating Sites (UAS). With virtually 100% animals affected as early as 2-3 days post-fertilization (dpf), HRAS V12 -expressing embryos rapidly develop prominent notochord hyperplasia that shares key histological features with human chordoma samples (24) .
Here, we applied this in vivo platform to test the potency of chordoma-implicated factors in driving notochord hyperplasia. We established transgenic zebrafish for col2a1aR2:KalTA4 for robust injection-based candidate gene expression with fluorescent tags in the developing notochord. col2a1aR2-driven transient mosaic expression of HRAS V12 triggered chordoma-like notochord hyperplasia akin to stable genetic insertions.
Notably, notochord-specific overexpression of human or zebrafish Brachyury, including a version with augmented transcriptional activity, failed to cause notochord hyperplasia in the observed timeframe of 5 dpf.
In contrast, overexpression of the chordoma-implicated RTKs EGFR and KDR/VEGFR2 potently induced a chordoma phenotype. Transcriptome sequencing and cellular ultrastructure analysis uncovered that Rasmediated RTK signaling drives excessive secretory pathway activity, extracellular matrix (ECM) buildup, and a suppression of the Unfolded Protein Response (UPR) in transformed notochord sheath cells. These processes hinder the transformed sheath cells from further differentiation, yet ultimately trap the hyperproliferating mass with its accumulating ECM. Taken together, our data indicate that Brachyury per se might be insufficient to initiate chordoma and rather reflects the maintained notochord lineage identity of the transformed cells. Our results instead propose that aberrant RTK signaling, possible by activation of several repeatedly chordoma-implicated RTK genes (7-10), presents a potent initial transformative event towards chordoma formation.
Methods

Animal husbandry
Zebrafish (Danio rerio) were maintained, collected, and staged principally as described (25) and in agreement with procedures mandated by the veterinary office of UZH and the Canton of Zürich. If not indicated otherwise, embryos up to 5 dpf were raised in temperature-controlled incubators without light cycle at 28°C.
Vectors and transgenic lines col2a1aR2:KalTA4 driver line:
The plasmid pE5'-col2a1aR2_minprom was cloned by amplifying the previously described col2a1aR2 cis-regulatory element (26) with the primers col2a1a R2 fwd and col2a1a R2 BamHI reverse from zebrafish genomic DNA using the Expand High Fidelity Polymerase System (Roche).
The resulting PCR product was TA-cloned into pENTR5' (Thermo Scientific) following the manufacturer's instructions. The mouse beta-Globin minimal promoter (minprom) was amplified from pME-minprom-EGFP (27) with the primers Mouse beta-Globin minimal promoter BamHI forward and Mouse beta-Globin minimal promoter XbaI reverse and cloned into pENTR5'-col2a1aR2. The final plasmid col2a1aR2:KalTA4,myl7:EGFP was assembled by Multisite Gateway Cloning (see Supplementary Methods for details on cloning, transgenesis, and additionally used transgenic lines).
Imaging and staining
Injected embryos were sorted by fluorescent dissecting scope-detectable notochord fluorescence (indicating the presence of the UAS-transgene) and imaged at 5 dpf. Animals with strong fluorescence were fixed in 4% PFA at 4°C overnight. Subsequently, embryos were embedded in paraffin, sectioned into 5 µm sections, deparaffinated, and stained with Hematoxylin and Eosin according to standard protocols.
Immunohistochemical studies were performed according to the manufacturers' protocol of the individual antibodies used (see Supplementary Methods for antibody details). Work on chordoma sections was performed under approval by BASEC-no. 2017-00017 by the Cantonal Ethics Commission Zürich. Live animals were imaged with a Leica M205FA stereo microscope. Histological sections were imaged with a Zeiss Axioscan Z1 Slidescanner using a Plan Apochromat 20x objective.
Transmission Electron Microscopy
Wildtype and HRAS V12 -expressing larvae where fixed 2.5% Glutaraldehyde at 8 dpf and processed for TEM at the Center for Microscopy and Image Analysis (ZMB), following standard protocols. Images were acquired with a Philips CM100 transmission electron microscope.
Notochord isolation and mRNA-Seq 8 dpf Tg(twhh:Gal4) and Tg(twhh:Gal4);Tg(UAS:EGFP-HRAS V12 ) were euthanized with 3% Tricaine methanesulfonate (Sigma). Embryos were decapitated and incubated in Trypsin-EDTA (Sigma) for 30 minutes to facilitate tissue dissociation. Notochords were then dissected using tungsten needles and immediately transferred to Trizol-LS (Ambion). We isolated 30-50 notochords per replicate, with a total of 3 replicates per condition (3x wildtype, 3x HRAS V12 ). Notochord RNA was extracted following the manufacturer's protocol using Trizol-LS. RNA-seq analysis was performed as outlined in Supplementary Methods.
Results
Sheath cell-directed oncogene expression drives chordoma formation in zebrafish
We first sought to functionally assess chordoma-associated genes that could initiate notochord hyperplasia in zebrafish embryos. While our previous chordoma modelling used as transgene driver twhh:Gal4, based on the twhh promoter region with promiscuous transcriptional activity in notochord cells (24, 28) , we aimed for a stronger driver that would also enable injection-based oncogene testing. We generated col2a1aR2:KalTA4 transgenics that base on the R2 fragment of the col2a1a regulatory region (26) to express the optimized Gal4based transactivator KalTA4 (28) ( Fig. 1A,B ). When incrossed with stable UAS reporters, col2a1aR2:KalTA4 drove notochord-specific reporter expression detectable from 5-7 somite stage (approximately 12 hpf) in the entire notochord including sheath cells, expression which remained strong throughout development ( Fig.   1A,B ). col2a1aR2 also drove KalTA4 expression in other cartilage lineages, including the otic vesicle, jaw, and pectoral fin starting from 2.5 to 3 dpf throughout adulthood ( Supplementary Fig. S1A -C), in agreement with previous analyses of R2 activity (26) .
When we crossed col2a1aR2:KalTA4 to stable UAS:EGFP-HRAS V12 , double-transgenic embryos displayed over-proliferation of notochord sheath cells within 2 dpf: sheath cell proliferation advanced over time towards the center of the notochord, effectively compressing the inner vacuoles and excluding them altogether in parts of the notochord (Fig. 1C ,D). This phenotype was similar, if not stronger, than the twhh:Gal4;UAS:EGFP-HRAS V12 combination used previously for chordoma modeling in zebrafish (24) . In addition to the uncontrolled proliferation of notochord cells, col2a1aR2:KalTA4;UAS:EGFP-HRAS V12 embryos developed enlarged otic vesicles and deformed jaw cartilage starting from 4 dpf ( Fig. 1C) , consistent with the overall expression pattern of the col2a1aR2:KalTA4 driver ( Fig. 1A ,C, Supplementary Fig. S1A -C). Taken together, these observations establish col2a1aR2:KalTA4 as potent driver for notochord-specific transgene expression and notochord hyperplasia in zebrafish.
T/Brachyury overexpression is insufficient to initiate notochord hyperplasia
Based on these results, we assessed if we can perform candidate gene tests by transforming notochord cells in transient injections into col2a1aR2:KalTA4 embryos ( Fig. 2A ). Closely resembling the phenotype of stable HRAS V12 overexpression ( Fig. 1C,D) , the transformed sheath cells locally invaded the notochord ( Fig. 2E ).
We next applied col2a1aR2:KalTA4 to test the potential of increased Brachyury activity to transform the developing notochord. We cloned UAS vectors harboring human Brachyury and its main zebrafish ortholog Supplementary Fig. S2G ,H). Contrary to humans and mice that harbor a single copy of the T/Brachyury gene, zebrafish harbor two paralogs, ntla and ntlb. Nonetheless, the overexpression of UAS:ntlb alone did not affect the integrity of the notochord (Fig. 2J,K) , nor did the combined overexpression of UAS:ntla and UAS:ntlb within the observed 5 days (Fig. 2L,M) .
To augment the activity of zebrafish ntla as transcriptional activator, we expressed a Ntla-VP16 fusion protein wherein native Ntla is fused with the strong VP16 transactivation domain (29) . col2a1aR2:KalTA4-driven notochord expression of transiently injected UAS:ntla-VP16 reproducibly resulted in embryos with severe body curvature, a shortened body axis, and cardiac edema, yet analyzed notochords remained structurally intact and devoid of any hyperplasia (Fig. 2N,O) .
Altogether, from these results within the timeframe of our observations, we conclude that increased expression of ntl/Brachyury, even of a transcriptionally hyperactive form, is per se insufficient to transform developing zebrafish notochord cells into a hyperplastic state.
Overexpression of RTK genes found activated in human chordoma is sufficient to initiate notochord hyperplasia
Receptor tyrosine kinases (RTKs) and their branched downstream pathways are key players in development, and activation of RTKs and their downstream Ras-dependent cascades can transform a variety of cell types into tumors (30) . While activated Ras mimics upstream RTK activation, as used in our original chordoma model (24) , Ras mutations are seemingly rare in chordoma (3, 31) . An increasing number of studies have rather found copy number alterations, increased phosphorylation, or misexpression of individual RTKs in chordoma, most prominently of EGFR, KDR/VEGFR2, PDGFRA, c-KIT, and different FGFR genes (7-10).
To test the potential of misexpressed individual RTKs for driving hyperplastic notochord transformation, we injected col2a1aR2:KalTA4 embryos with UAS constructs harboring the ORFs of candidate RTKs and additional chordoma-implicated candidate genes as reference. Injection of UAS constructs for c-KIT, PDGFRA, FGFR3, and FGFR4 all resulted in high mortality rates during somitogenesis (>80% in the case of FGFR3 and FGFR4): in injected embryos, we frequently observed severe body axis perturbations and dorsoventral patterning defects ( Supplementary Fig. S3A-D) . These phenotypes suggest severe non-autonomous effects upon notochord-focused expression of c-KIT, PDGFRA, FGFR3 and FGFR4, precluding further analysis using our approach. In contrast, and comparable to injection of UAS-HRAS V12 (Fig. 3A-D) , notochorddriven expression of UAS:EGFR caused reproducible sheath cell hyperplasia between 2-5 dpf (Fig. 3E,F) .
Similarly, injection of UAS:kdr/vegfr2 also potently triggered sheath cell hyperplasia ( Fig. 3G,H) . Both EGFRand Kdr/Vegfr2-expressing notochords displayed localized hyperplasia along the entire length of the notochords (Fig. 3F,H) : we repeatedly observed clusters of hyperproliferating sheath cells invading the center of the notochord, thereby compressing the vacuolated inner notochord cells, as also observed by HRAS V12 expression ( Fig. 2E,3D ).
Phosphorylation of mTOR, a key downstream mediator of RTK/Ras signaling in the mTORC1 and mTORC2 complexes in the control of ribosome biogenesis and protein synthesis, has been repeatedly found in chordoma (32) . The small GTPase Rheb activates mTORC1 and can act upon overexpression as a protooncogene (33, 34) . col2a1a:KalTA4 embryos injected with UAS:rheb developed notably larger vacuolated notochord cells ( Fig. 3I ,J), in agreement with increased cell growth triggered by mTOR1 activity; nonetheless, the UAS:rheb-injected embryos did not develop any notochord hyperplasia within the observed 5 dpf ( Fig.   3I ,J). We further tested the tumorigenic potential of STAT3 involved in JAK/STAT signaling which has been repeatedly found activated in chordoma (31, 35) . Nonetheless, col2a1aR2:KalTA4 embryos expressing UAS:stat3 also developed normally without any signs of notochord hyperplasia (Fig. 3K,L) . Taken together, our results suggest that of the genes we tested in our assay, misexpression of chordoma-implicated EGFR and KDR/VEGFR2 RTKs is sufficient to trigger the onset of specific notochord hyperplasia.
We confirmed that EGFR-and kdr/vegfr2-misexpressing cells have activated MAPK signaling, as revealed by probing for the downstream effector pERK: compared to 5 dpf wildtype notochords that are devoid of pERK ( Fig. 4A) , HRAS V12 , EGFR, and kdr/vegfr2 misexpression resulted in pERK-positive notochord cells, including prominent staining in cells infiltrating the notochord (Fig. 4B-D) . Compared to controls, the HRAS V12 -, EGFR-, and kdr/vegfr2-overexpressing notochords also stained notably stronger for the common chordoma marker pan-Cytokeratin ( Fig. 4F-I) . We also observed staining for zebrafish Brachyury protein Ntla ( Fig. 4K-O; see Supplementary Fig. S4A -G for human Brachyury antibody). Consistent with the absence of hyperplastic cells, combined overexpression of the zebrafish Brachyury genes ntla and ntlb did not change the staining for any of these markers (except for the misexpressed Ntla itself) compared to wildtype (Fig. 4E,J,O) . These observations suggest that commonly used diagnostic markers for human chordoma stain positive in hyperplastic zebrafish notochords with activated RTK signaling.
Taken together, in zebrafish, increased levels of EGFR and KDR/VEGFR2 are sufficient to induce hyperplasia of developing notochord sheath cells by triggering RTK signaling, akin to constitutively active HRAS V12 . In contrast, notochord-specific expression of effectors driving mTOR or JAK/STAT signaling, as 9 also of different versions of Brachyury (Fig. 2F-O) , did not trigger over-proliferation with early onset. These observations raise the possibility that aberrant activation of RTK signaling is a key process to trigger notochord cell hyperplasia, while other chordoma-implicated mechanisms could then potentially contribute after the initial tumor onset.
Ras-mediated notochord transformation in zebrafish recapitulates abnormalities found in human chordoma
To gain more insight into the initial phase of notochord hyperplasia triggered by Ras-mediated notochord transformation in zebrafish, and to assess if genes associated with human chordoma become de-regulated, we performed RNA-seq analysis of dissected wildtype versus HRAS V12 -transformed notochords (Fig. 5A ).
We found a total 591 genes as significantly deregulated in hyperplastic notochords compared to wildtype (228 upregulated, 363 downregulated; minimum log fold change ≥1, corrected FDR ≤0.05) ( Fig. 5B , Supplementary Table S1 ). Notably, in the analyzed zebrafish control notochords, we detected modest but significant expression of both zebrafish Brachyury-coding genes ntla and ntlb, as confirmed by RT-PCR ( Fig.   5B , S5A-C). Neither ntla nor ntlb significantly changed upon HRAS V12 transformation ( Supplementary Fig.   S5A -C, Supplementary Table S1 ). These data indicate that, in the developing notochord, the expression of the zebrafish Brachyury genes ntla and ntlb persists beyond initial embryonic stages for considerably longer than commonly assumed based on mRNA in situ hybridization (36).
Among the significantly deregulated genes, we found genes that have previously been implicated in being aberrantly expressed in human chordoma. For instance, loss of the BCL6 locus has been reported as possibly frequent event in chordoma (6) . Consistent with this notion, all zebrafish bcl6 genes, in particular bcl6ab, were significantly downregulated in our HRASV 12 -transformed zebrafish notochords ( Fig. 5B ,C, Supplementary   Table S1 ). Further, S100A1 is a potent diagnostic marker in clinical chordoma cases; zebrafish s100a1 was also the most-significantly upregulated s100 gene in our hyperplastic zebrafish notochords, albeit under slightly less stringent FDR threshold (logFC= 2.32, p=0.006, FDR=0.096) ( Fig. 5B ,C, Supplementary Table   S1 ). We conclude that despite species differences, the induction of notochord hyperplasia in zebrafish using activation of the RTK/Ras cascade also deregulates genes observed in human chordoma.
We additional performed downstream pathway analysis of the deregulated genes using both Ingenuity Pathway Analysis and Gene Set Enrichment Analysis. Interestingly, both of these analyses revealed a significant downregulation of genes associated with ER stress and with the unfolded protein responses (Fig.   5D ,E, Supplementary Fig. S5D-G) . Given the established roles of UPR in notochord development and differentiation towards mineralized bone (19) (20) (21) , this data suggests that one of the earliest responses to RTK/Ras transformation of the notochord is a suppression of this normal developmental program. Supporting this notion, other affected pathways included processes involved in bone and cartilage biology, including deregulation of markers of bone differentiation such as spp1, anxa5, and ihh ( Supplementary Fig. S5E,G) . In addition, we also noted a significant dysregulation of genes associated with extracellular matrix remodeling ( Fig. 5E ), a process associated with notochord sheath cells for building up a thick ECM around the forming notochord before the onset of segmented ossification (26, 37) . Taken together, the transcriptome of notochord cells transformed by activated RTK/Ras signaling shows hallmarks of suppressed notochord differentiation.
To observe the cellular consequences of early notochord transformation as indicated by our transcriptome analysis, we performed electron microscopy (EM). Transverse sections analyzed by EM again documented the invasion of outer sheath cells towards the center of the notochord, resulting in compression of the inner vacuoles ( Supplementary Fig. S6A,B) . Strikingly, and in contrast to the small elliptical nuclei that occur in wildtype sheath cells, transformed notochord cells developed highly enlarged nuclei with irregular and lobulated shapes (Fig. 6A,B) , as described previously (38) . Notably, transformed notochord cells showed an increase in ER membranes throughout the analyzed transformed sheath cells (Fig. 6A,B) , indicating highly active secretion that builds up unorganized ECM layers (Fig. 6C,D, Supplementary Fig. S6 ). Zebrafish chordomas generated with our approach do not metastasize  this study) but remain confined to the notochord. The ECM could, ultimately, be the cause for the absence of detectable outgrowth from the notochord in our zebrafish model: we observed several instances of individual sheath cells that had seemingly detached from the notochord and had become completely entombed within the secreted ECM ( Fig.   6D ). We detected a high abundance of secretory vesicles budding with the cell membrane in wildtype notochords, while transformed notochord cells featured amorphic cell boundaries to the ECM with trapped membrane fragments embedded in the collagen matrix ( Fig. 6E,F) .
Taken together, these observations suggest that RTK/Ras cascade-triggered sheath cell hyperplasia features hallmarks of deregulated ER stress and UPR. Oncogenic transformation by aberrantly activated RTK signaling could therefore drive the maintenance of an incompletely differentiated, developmental state in transformed notochord cells. In contrast, Brachyury expression is ongoing in the zebrafish notochord both in wildtype and in transformed conditions, indicating that maintained Brachyury expression reflects notochord identity of the transformed cells.
Discussion
While assumed to represent a notochord-derived tumor, the exact ontogeny and hyperplasia-inducing events leading to chordoma remain unclear. To our knowledge, activating Ras mutations have so far not been reported from chordoma samples, and a comprehensive comparison of the zebrafish-based chordoma transcriptome with human chordoma is hindered by the lack of readily accessible transcriptome data of this rare tumor. Nevertheless, several RTK genes have been repeatedly found aberrantly activated or amplified in human chordoma samples. Harnessing our zebrafish-based notochord readouts as proxy for chordoma onset, we evaluated the potential of several chordoma-implicated candidate genes for their capacity to transform native notochord cells in vivo, both with injection and verified with stable transgenic insertions. In our assays, the RTKs EGFR and KDR/VEGFR2, both abundantly found as oncogenes in various other cancer types, robustly triggered notochord hyperplasia. In contrast, overexpression of various forms encoding Brachyury, including as hyperactive VP16 fusion protein, caused no apparent notochord transformation in our observed timeframe. These results provide the first direct, functional testing of the chordoma-inducing potential of implicated oncogenes in native notochord cells.
We performed overexpression of Brachyury in the developing notochord by different means to avoid use of functionally impaired fusion proteins ( Supplementary Fig. S2A-E) . Misexpression of human Brachyury as well as individual or combinatorial expression of the zebrafish Brachyury genes ntla and ntlb (most-recently renamed tbxta and tbxtb), consistently failed to induce notable notochord hyperplasia ( Fig. 2F-M) . Of note, their misexpression did occasionally cause aberrant notochord architecture, with collapsed sheath cells reminiscent of recent reports of structural lesions in notochord morphology (Fig. 2H,I) (39) . Most compelling is the inability of ntla-VP16 to transform the notochord: ntla-VP16 encodes a previously validated (29) , highly transcriptionally active fusion protein through the viral VP16 transactivation domain (Fig. 2N,O) . These results provide first in vivo evidence that, in the zebrafish within the first 5 days, misexpression of Brachyury in developing notochord cells is insufficient to elicit a hyperplastic response.
Besides Brachyury, pathological detection of several other factors has been recurrently reported in chordoma cases. Ras/PI3K/AKT pathway activators, mainly RTKs including EGFR and KDR/VEGFR2, are frequently found activated or even genetically amplified in chordoma patients (7) (8) (9) (10) 32) . Further, promising advances in experimental chordoma treatment have been using RTK inhibitors, specifically compounds targeting EGFR (40, 41) . Our results from assessing the hyperplasia-inducing potential of individual factors suggest that several RTKs are potent, and possibly redundant, oncogenes when aberrantly activated in notochord cells ( Fig. 3E-H) . While RTKs relay critical signals during embryo development, as underlined by the severe developmental defects caused by notochord-focused misexpression of FGFR, Kit, and PDGFR genes ( Supplementary Fig. S3A-D) , the repeatedly chordoma-associated EGFR and KDR/VEGFR2 are, in our assay, individually sufficient to transform developmental notochord cells (Fig. 3E-H) . Phosphorylated mTOR, the core component of mTORC1 and mTORC2 downstream of activated RTKs, was found in a number of chordoma cases (4, 32, 42) . Nonetheless, activating mTORC1 via misexpression of its direct upstream regulator Rheb only results in morphological changes without hyperplasia (Fig. 3I,J) , suggesting that additional events downstream of RTK/Ras activation are required for triggering notochord hyperplasia.
STAT3-based signaling has been implicated in several chordoma studies (43) , yet does not seem to be universally activated in chordoma. In our assay, misexpression of STAT3 had no discernible impact on the notochord (Fig. 3K,L) , suggesting the potential of STAT3 to promote chordoma could contribute after the tumor-initiating hits.
Of note, our results with negative hyperplasia outcome do not rule out a chordoma-promoting potential for Brachyury, STAT3, or any other tested factor. Our assay is confined to an early developmental time window, which has the potential to reveal the sufficiency of aggressive notochord-transforming factors. Our results rather suggest that the chordoma-initiating events are most-potently mediated by triggering upstream events of RTK signaling; further work is warranted to analyze the synergy and combinatorial action of the individual chordoma lesions found in particular patients or across the analyzed tumors so far. In particular, the striking consistency of Brachyury expression in chordoma has gathered increasing attention as tumor-defining and possibly causative characteristic, pointing at the re-activation or maintenance of the embryonic notochord program as culprit (12, 14, 44, 45) . Nonetheless, developmental perturbation of Brachyury during mouse notochord formation suggests a role in maintaining cellular notochord identity, without impact on proliferation or other cellular phenotypes upon perturbation (17) . Further, the relevance of Brachyury expression for patient outcome remains unclear.
Two possibilities could account for the prominent expression of Brachyury in chordoma. First, in line with previous reports (17, 27) , Brachyury expression reflects the notochord identity of transformed notochord remnants. Several upstream signaling pathways influence Brachyury expression during development by acting on cis-regulatory elements that remain incompletely charted. Consequently, Brachyury expression in transformed notochord cells might simply reflect the sustained activity of the developmental notochord program. This conclusion is further supported by our observation of persistent ntla/ntlb expression in zebrafish that did not significantly react to RTK/Ras activation ( Fig. 5B, Supplementary Fig. S5B ,C, Supplementary   Table S1 ), and similar reports of sustained Brachyury expression in mouse (17) and human (46). Alternatively, not acting as transforming agent by itself, Brachyury expression could feed into the aberrant transcriptional program ongoing in chordoma cells after initial transformation. In chordoma, concomitant elevated Brachyury expression could result in additional or combinatorial events that direct RTK-transformed cells into a hyperproliferative state conductive to tumor progression and metastasis formation. Congenital amplification of the Brachyury locus could confer sensitivity to notochord cells for aberrant RTK activation and for subsequently faster tumor formation (14) . Brachyury knockdown in the developing notochord in mouse 13 has revealed that its function was dispensable for progenitor cell survival, proliferation, and EMT (17) .
Expressed beyond physiological levels for a prolonged time, Brachyury could nonetheless contribute aberrantly to tumorigenic events. Brachyury can influence the RTK-based FGF pathway by controlling production of the FGF2 ligand to possibly maintain a positive feedback loop, resulting in a mesenchymal phenotype (47, 48) .
Our RNA-seq analysis of Ras-transformed zebrafish notochords mimicking activated RTK signaling revealed deregulation of clinically relevant chordoma genes, including s100a1 and bcl6 family members (Fig. 5) . These changes were concomitant with alterations in UPR, ER stress response, and ECM pathways ( Fig. 5,   Supplementary Fig. S5 ). Ultimately, the excessive accumulation of ECM collagen sheets around the transformed notochord likely hinders the hyperplastic cells in their expansion (Fig. 6 ). Hence, RTK-based transformation alone might skew notochord cells into a cellular state that caps their proliferative and invasive potential. Consistent with this notion, we detected deregulated UPR and ER stress pathways, which were accompanied by excessive ECM buildup that ultimately entombed individual cells (Fig. 6E,F) . Coordinated activation of secretory pathway features with concomitant activation of the UPR is a hallmark of progressive notochord differentiation in medaka and Xenopus (19, 21, 49) . The prominent secretory activity of differentiating notochord cells, in particular collagen secretion and ECM buildup, requires careful fine-tuning by the UPR to prevent apoptosis and aberrant protein accumulation in the ER (50). We therefore hypothesize that the suppression of an UPR and ER stress signature upon RTK/Ras activation in notochord cells prevents their terminal differentiation, keeping them in a proliferative, progenitor-like state that is susceptible to additional oncogenic insults. Therapeutic targeting of RTK signaling could consequently attack a main pathway required for the initial transformation of native notochord cells towards chordoma. mechanism in chordoma(#). J Pathol. 228, 261-265 (2012 
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